OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Interactive ToolsLearning ModulesPresentationsSponsored
Biomarker Consortium
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • 2024 nominations are open for Giants of Cancer Care®
  • In-person and virtual events just for HCPs
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
    • Biomarker Consortium
Advertisement

Melanoma Mortality Is Related to Dermatologist Density

May 18, 2012
Jill Stein
Publication
Article
Oncology & Biotech NewsMay 2012
Volume 6
Issue 5

Within a given county in the United States, the presence of a dermatologist is associated with a lower melanoma mortality rate compared with counties where there is no dermatologist.

Jeremy S. Bordeaux, MD

Within a given county in the United States, the presence of a dermatologist is associated with a lower melanoma mortality rate compared with counties where there is no dermatologist, recent data suggest.

Jeremy S. Bordeaux, MD, director of Mohs Micrographic and Dermatologic Surgery at University Hospitals Case Medical Center, Cleveland, Ohio, and coworkers examined the association between melanoma-related deaths and dermatologist density.

The investigators used a merged dataset from the National Program for Cancer Registries, the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program, and the Centers for Disease Control and Prevention’s National Vital Statistics System for the time period from January 2002 through December 2006.

The availability of information on the regional distribution of dermatologists is requisite for developing healthcare policies that aim to improve patient outcomes.

The analysis included 2472 counties with a total population of 225,981,679 people. The primary outcome measure was melanoma mortality rate per 100,000 people at the county level.

Results showed that the numbers of dermatologists and subspecialist density varied from city to city, with some areas having no such physicians at all. The presence of 0.001 to one dermatologist per 100,000 people was associated with a lower melanoma mortality rate by more than one-third compared with counties that lacked dermatologists. More than one to two dermatologists per 100,000 people was associated with a 53.0% reduction in melanoma mortality (95% CI, 30.6%-75.4%). The addition of more than two dermatologists per 100,000 people did not confer additional benefit.

The study found that there were no dermatologists in a large portion of the country. There was a higher density of dermatologists along the Pacific Coast, throughout the state of Hawaii, and in clusters in the Midwest and along the East Coast.

The authors cited as a drawback to their study the exclusion of rural counties. They said that they excluded rural counties because there were limited mortality data from these areas and few rural counties had any dermatologists.

They added that efforts to draw dermatologists to counties where there were no dermatologists may yield a population-wide reduction in melanoma mortality. However, they were quick to emphasize that recruiting more dermatologists to counties where there already were dermatologists probably wouldn’t have much of an impact on melanoma mortality since “having two dermatologists is not statistically different from having four dermatologists when considering mortality rates,” the researchers said.

The authors concluded that more research is needed to determine whether dermatologist density is associated with early diagnosis of melanoma or improved treatment.

Aneja S, Aneja S, Bordeaux JS. Association of increased dermatologist density with lower melanoma mortality. Arch Dermatol. 2012;148(2):174-178. doi:10.001/archdermatol.2011.345.

Articles in this issue

Semuloparin Is Effective and Safe for Antithrombotic Prophylaxis in Cancer Patients
Semuloparin Is Effective and Safe for Antithrombotic Prophylaxis in Cancer Patients
University of Michigan Comprehensive Cancer Center: Leading the Way in Targeted Therapies Cancer Care
University of Michigan Comprehensive Cancer Center: Leading the Way in Targeted Therapies Cancer Care
Unraveling the Complexity of Drug Shortages: Grim Reality Is a Bitter Pill to Swallow
Unraveling the Complexity of Drug Shortages: Grim Reality Is a Bitter Pill to Swallow
Docetaxel in Combination With Novel Therapies in Prostate Cancer: Promising Phase III Trials Ongoing
Docetaxel in Combination With Novel Therapies in Prostate Cancer: Promising Phase III Trials Ongoing
Targeted Focal Therapy Emerges as Alternative to Active Surveillance or Definitive Treatment
Targeted Focal Therapy Emerges as Alternative to Active Surveillance or Definitive Treatment
Surgery for Colorectal Cancer Hepatic Metastases Has Little Effect on Health
Surgery for Colorectal Cancer Hepatic Metastases Has Little Effect on Health
Prostate Cancer Screening: A Q&A With Oliver Sartor, MD, and Leonard G. Gomella, MD
Prostate Cancer Screening: A Q&A With Oliver Sartor, MD, and Leonard G. Gomella, MD
Younger Age, Recent Surgery, and Lymphedema Influence Decision for Repeat Mammogram in Breast Cancer Survivors
Younger Age, Recent Surgery, and Lymphedema Influence Decision for Repeat Mammogram in Breast Cancer Survivors
NCCN 17th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care
NCCN 17th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care
Politics and Science Intersect in PSA Screening
Politics and Science Intersect in PSA Screening
Melanoma Mortality Is Related to Dermatologist Density
Melanoma Mortality Is Related to Dermatologist Density
Colonoscopy Recommendation May Cut Adherence to CRC Screening
Colonoscopy Recommendation May Cut Adherence to CRC Screening
Premature Aromatase Inhibitor Discontinuation Is Common
Premature Aromatase Inhibitor Discontinuation Is Common
Bending the Cost Curve and Here Come the Judge(s)
Bending the Cost Curve and Here Come the Judge(s)
Related Videos
Paul D. Nathan, MBBS, PhD, FRCP
Paul D. Nathan, MBBS, PhD, FRCP
Jeffrey S. Weber, MD, PhD
Omid Hamid, MD
Elizabeth Buchbinder, MD
Related Content
Advertisement
FDA

FDA Grants Clearance for Phase 1/2 Trial of eTIL KSQ-001EX in Solid Tumors

November 30th 2023
Article
Jeffrey S. Weber, MD, PhD

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

November 6th 2023
Podcast
Paul Nathan, MBBS, PhD, MRCP

Tebentafusp Sustains OS Benefit in Previously Untreated, Metastatic Uveal Melanoma

November 20th 2023
Article
Nikhil I. Khushalani, MD; Martin F. Dietrich, MD, PhD; Jason J. Luke, MD, FACP; Vishal A. Patel, MD, FAAD, FACMS

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

March 6th 2023
Podcast
Elizabeth I. Buchbinder, MD

Retrospective Study Shows Nivolumab Associated With OS Benefit After Nivolumab/Ipilimumab irAEs in Advanced Melanoma

November 4th 2023
Article
Danielle K. DePalo, MD

Multidisciplinary Consideration of Frontline Modalities Should Guide Decisions in Melanoma With In-Transit Metastases

October 24th 2023
Article
Related Content
Advertisement
FDA

FDA Grants Clearance for Phase 1/2 Trial of eTIL KSQ-001EX in Solid Tumors

November 30th 2023
Article
Jeffrey S. Weber, MD, PhD

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

November 6th 2023
Podcast
Paul Nathan, MBBS, PhD, MRCP

Tebentafusp Sustains OS Benefit in Previously Untreated, Metastatic Uveal Melanoma

November 20th 2023
Article
Nikhil I. Khushalani, MD; Martin F. Dietrich, MD, PhD; Jason J. Luke, MD, FACP; Vishal A. Patel, MD, FAAD, FACMS

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

March 6th 2023
Podcast
Elizabeth I. Buchbinder, MD

Retrospective Study Shows Nivolumab Associated With OS Benefit After Nivolumab/Ipilimumab irAEs in Advanced Melanoma

November 4th 2023
Article
Danielle K. DePalo, MD

Multidisciplinary Consideration of Frontline Modalities Should Guide Decisions in Melanoma With In-Transit Metastases

October 24th 2023
Article

Latest Conference Coverage

Ribociclib Plus Endocrine Therapy Improves PFS and OS in Elderly Patients With HR+/HER2– Breast Cancer

Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care

Dr Habib on Developments in Palliative Care For Patients With Cancer

Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact